Hemostatic Disorders in Type 1 Diabetes Mellitus

被引：34
作者：
Targher, Giovanni [1 ]
Chonchol, Michel [2 ]
Zoppini, Giacomo [1 ]
Franchini, Massimo [3 ]
机构：
[1] Univ Verona, Dept Med, Endocrinol Sect, I-37126 Verona, Italy
[2] Univ Colorado, Denver Hlth Sci Ctr, Div Renal Dis & Hypertens, Aurora, CO USA
[3] Univ Hosp Parma, Immunohematol & Transfus Ctr, Dept Pathol & Lab Med, Parma, Italy
来源：
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2011年 / 37卷 / 01期
关键词：
Type; 1; diabetes; coagulation; fibrinolysis; hemostatic disorders; ACTIVATABLE FIBRINOLYSIS INHIBITOR; SOLUBLE CD40 LIGAND; ENDOTHELIAL DYSFUNCTION; MICROVASCULAR COMPLICATIONS; ADHESION MOLECULES; MARKERS; INFLAMMATION; ASSOCIATION; NEPHROPATHY; COAGULATION;
D O I：
10.1055/s-0030-1270072
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This review summarizes current knowledge of the adverse effects of type 1 diabetes mellitus on coagulation and fibrinolysis. Although further larger studies are needed to provide more definitive information, patients with type 1 diabetes exhibit a proinflammatory/procoagulant condition deriving from increased platelet adhesiveness, activation of the coagulation system, and decreased plasma fibrinolytic potential. This review also focuses on recent data from large prospective studies suggesting a strong association between procoagulant imbalance and development of chronic vascular complications in people with type 1 diabetes. It is likely that a greater appreciation of the intimate interactions between endothelial integrity, coagulation and fibrinolytic factors, and platelets in type 1 diabetes will provide a greater understanding of the risk of developing cardiovascular disease and microvascular complications such as nephropathy and retinopathy in this patient population.
引用
收藏
页码：58 / 65
页数：8
相关论文
共 44 条
[1]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[2]   Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications [J].
Antovic, JP ;
Yngen, M ;
Östenson, CG ;
Antovic, A ;
Wallen, HN ;
Jorneskög, G ;
Blombäck, M .
BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (06) :551-556
[3]   Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years - Association with mortality and decline of glomerular filtration rate [J].
Astrup, Anne Sofie ;
Tarnow, Lise ;
Pietraszek, Lotte ;
Schalkwijk, Casper G. ;
Stehouwer, Coen D. A. ;
Parving, Hans-Henrik ;
Rossing, Peter .
DIABETES CARE, 2008, 31 (06) :1170-1176
[4]  
Blann AD, 1998, DIABETIC MED, V15, P634, DOI 10.1002/(SICI)1096-9136(199808)15:8<634::AID-DIA636>3.3.CO
[5]  
2-#
[6]   The pathobiology of diabetic complications - A unifying mechanism [J].
Brownlee, M .
DIABETES, 2005, 54 (06) :1615-1625
[7]   COAGULATION AND FIBRINOLYTIC SYSTEM IMPAIRMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
CARMASSI, F ;
MORALE, M ;
PUCCETTI, R ;
DENEGRI, F ;
MONZANI, F ;
NAVALESI, R ;
MARIANI, G .
THROMBOSIS RESEARCH, 1992, 67 (06) :643-654
[8]   Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications study [J].
Costacou, T ;
Lopes-Virella, MF ;
Zgibor, JC ;
Virella, G ;
Otvos, J ;
Walsh, M ;
Orchard, TJ .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2005, 19 (04) :183-193
[9]   Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus -: Role of interleukin-6 and disease duration [J].
Davì, G ;
Chiarelli, F ;
Santilli, F ;
Pomilio, M ;
Vigneri, S ;
Falco, A ;
Basili, S ;
Ciabattoni, G ;
Patrono, C .
CIRCULATION, 2003, 107 (25) :3199-3203
[10]   Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes [J].
Devaraj, S ;
Glaser, N ;
Griffen, S ;
Wang-Polagruto, J ;
Miguelino, E ;
Jialal, I .
DIABETES, 2006, 55 (03) :774-779
12345